Search for Current Clinical Trials

Study Name Description Trial Category Trial SubCategory
EAY191-A6 ComboMATCH The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. Cancer Biliary
EAY191-E4 ComboMATCH The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. Cancer Solid Tumors
EAY191-N2 ComboMATCH This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. Cancer Metastatic Breast
EAY191-N4 The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. Cancer Ovarian & Endometrial
EAY191-S3 ComboMATCH The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. Cancer Solid Tumors (non-breast)
ISPY 2 This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. Cancer Breast
NRG-GI008 The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. Cancer Colon
NRG-GU009 The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with high-risk prostate cancer. Cancer Prostate
NRG-GU010 The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with unfavorable intermediate risk prostate cancer. Cancer Prostate
NRG-LU008 The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). Cancer Non-Small Cell Lung
S1803 The purpose of this study is to compare daratumumab and lenalidomide vs lenalidomide alone for maintenance therapy after stem cell transplant. You must be diagnosed with multiple myeloma. Cancer Multiple Myeloma
S1900E (LUNGMAP sub study) The purpose of this study is determine if the use of Sotorasib is effective in patients with previously treated stage 4 or recuurent KRAS G12C mutated non-squamous non-small cell lung cancer (NSCLC). You must be diagnosed with NSCLC with a KRAS G12C mutation. Cancer Metastatic Non-Small Cell Lung
S1914 This study is comparing the use of Atezolizumab + SBRT (stereotactic body radiation therapy) vs SBRT Alone in high risk early stage non-small cell lung cancer (NSCLC). You must be diagnosed with stage 1 or 2 non-small cell lung cancer (NSCLC). Cancer Non-Small Cell Lung
S1922 The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. Cancer Small Bowel
S2001 The purpose of this study is to determine the effectiveness of Olaparib + Prembrolizumab vs Olaparib alone. You must be diagnosed with metastatic pancreatic cancer with a BRCA1 or BRCA2 mutation. Cancer Pancreatic
S2107 The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic colorectal cancer. Cancer Metastatic Colorectal
S2200 The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. Cancer Metastatic Renal Cell
S2212 The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. Cancer Breast
S2302 This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC). Cancer Metastatic Non-Small Cell Lung
URCC 18007 A study see if Bupropion is effective for reducing cancer-related fatigue. You must have completed surgery, radiation and/or IV chemo at least 2 months prior to enrollment. Cancer All tumor types
A022101 The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. Cancer Colorectal
A022102 The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. Cancer Esophageal
A022104 The purpose of this study is to look at the effectiveness of two chemo regimens mFOLFOX6 or CAPOX vs mFOLFIRINOX in getting patients to remission. You must be diagnosed with stage 2 or 3 rectal cancer. Cancer Rectal
Destiny 614 This is an open-label, multi-center, long-term study of patients with genetically-confirmed Prader-Willi Syndrome (PWS). Endocrinology Pediatrics
Librexia AF The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation. Heart & Vascular Atrial Fibrillation
ANT-010/Lilac A study to evaluate the effect of the experimental drug abelacimab relative to placebo in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners. Heart & Vascular Atrial Fibrillation
ESsCAPE The main objective of the trial is to assess the efficacy and safety of the drug trimodulin as adjunctive treatment to standard of care compared to placebo plus standard of care in adults hospitalized with severe community-acquired pneumonia on invasive mechanical ventilation. Pulmonary Respiratory
Amgen Ocean(a) The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Patients must have a Lp(a) value of ≥ 200 nmol/L during screening. Heart & Vascular Cardiovascular Disease
Amplitude This research study is a way to find out if the Study Drug is safe and if it works to help people with APOL-1 mediated Chronic Kidney Disease. Nephrology Proteinuric Kidney Disease
Amulet Patients will have nonvalvular atrial fibrillation. This irregular beating of the heart leads to a slowing of the blood flow in the upper chambers of the heart. In the left upper chamber, there is a small pouch called the left atrial appendage (LAA). Slowing of blood, especially in the LAA, may cause blood clots to form. Blood clots can move from the LAA and travel to the brain, causing a stroke or transient ischemic attack (TIA), also called a mini-stroke. These blood clots can also travel to other parts of the body and block blood vessels. The Amulet device could be beneficial because it may lower the chance of a new blood clot forming and moving from the heart’s LAA to other parts of your body. Heart & Vascular Structural Heart Disease